Translation for 'orexin' from English to French

orexin

orexine {f}biol.

• Orexin-A, also known as hypocretin-1, is a naturally occurring neuropeptide and orexin isoform.
• Through the diverse outputs of the orexin system, the orexin neurons in the lateral hypothalamus mediate an array of functions.
• Suntinorexton (...) is an experimental orexin receptor agonist. It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.
• TAK-994 is an orexin receptor agonist which is under development by Takeda for the treatment of narcolepsy.
• ACT-335827 is an orally available, selective orexin 1 receptor antagonist with anxiolytic effects in animals.

• The endogenous orexin neuropeptides, orexin A and orexin B, are involved in the regulation of sleep–wake cycles and act to promote wakefulness.
• Tropoflavin was also found to decrease mouse sleep in dark phase and reduce hypothalamus level of orexin A but not orexin B in mice.
• Research suggests that orexin and histamine neurons play distinct, but complementary roles in controlling wakefulness with orexin being more involved with wakeful behavior and histamine with cognition and activation of cortical EEG.
• Ten years later, this led to the discovery that mutations in the hypocretin (orexin) receptor 2 cause canine narcolepsy, and that human narcolepsy was caused by an immune mediated destruction of the hypocretin (orexin) producing cells in the brain Parallel work performed by Mashashi Yanagisawa, Christopher Stinton and colleagues subsequently showed that hypocretin (orexin) deficient mice also have narcolepsy.
• An orexin receptor antagonist, or orexin antagonist, is a drug that inhibits the effect of orexin by acting as a receptor antagonist of one or both of the orexin receptors, OX1 and OX2.

• Suvorexant is thought to exert its therapeutic effects in the treatment of insomnia by blocking the orexin receptors and thereby inhibiting the effects of the endogenous wakefulness-promoting orexin neuropeptides orexin-A and orexin-B.
• TCS-OX2-29 is an orexin antagonist. It was the first non-peptide antagonist developed that is selective for the orexin receptor subtype OX2, with an IC50 of 40nM and selectivity of around 250x for OX2 over OX1 receptors.
• Mice models have also been used to test whether the lack of orexin neurons is correlated with narcolepsy.
• RTIOX-276 is an orexin antagonist. RTIOX-276 binds selectively to the orexin 1 receptor (KE = 8.5nM) and lacks significant affinity for the orexin 2 receptor (KE = > 10,000nM).